

## POSITION STATEMENT

### **Mounjaro® (tirzepatide) for managing overweight and obesity in primary care**

**Updated June 2025**

#### **Recommendation:**

Mounjaro® (Tirzepatide) for managing overweight and obesity in primary care  
– **LSCMMG RAG status 'Do Not Prescribe'**

**Please note:** Do not prescribe in primary care until further notice and refrain from referring to specialist weight management services until commissioning pathways have been clarified by the ICB.

**It is expected that the RAG position will be updated periodically and in line with the implementation plan.**

NHSE published an update in March 2025 outlining the implementation plan of NICE TA 1026, addressing the challenges and strategies for integrating this treatment into NHS services.<sup>1</sup>

NHS England recognises the resource and cost impact of NICE TA 1026 and intends to provide additional funding to ICBs to support with:

- Medication costs related to prescribing obesity treatments [GLP-1s and GIP/GLP-1s] across all care settings for NHS England's prioritised patient cohort only; and,
- Management costs related to prescribing weight management services in a primary care setting.

As the intention is to centrally arrange wrap-around care during 2025/26, NHS England will retain funding for these services, which will be made available at no cost to ICBs.

#### **References**

1. Interim commissioning guidance: implementation of the NICE technology appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro®) for the management of obesity. Accessed via:  
<https://www.england.nhs.uk/publication/interim-commissioning-guidance-implementation-of-the-nice-technology-appraisal-ta1026-and-the-nice-funding-variation-for-tirzepatide-mounjaro-for-the-management-of-obesity/> (accessed online 16/4/25)